AcelRx slumps as FDA demands another Zalviso trial
This article was originally published in Scrip
AcelRx Pharmaceuticals saw its share price slump on news that the US FDA now wants an additional clinical trial conducted "to assess the risk of inadvertent dispensing and overall risk of dispensing failures" of Zalviso, said the Redwood City, CA-based firm. Zalviso is a pre-programmed, non-invasive, handheld system, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain. Last July, in a surprise move, the FDA rejected Zalviso's NDA. However, the complete response letter did not mention the need for additional clinical data. AcelRx now plans to meet with the FDA to clarify the situation and discuss the potential design and objectives of new study. An NDA resubmission for Zalviso will not happen this quarter, as previously planned. AcelRx will provide an update on the timing of the resubmission of the Zalviso NDA after meeting with the FDA, it said.
You may also be interested in...
AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.